<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01563237</url>
  </required_header>
  <id_info>
    <org_study_id>INN004</org_study_id>
    <nct_id>NCT01563237</nct_id>
  </id_info>
  <brief_title>Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant</brief_title>
  <official_title>Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) to Relieve Glaucoma Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InnFocus Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InnFocus Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and performance of the MIDI Arrow in patients suffering from glaucoma
      that is inadequately controlled on maximum tolerated medical therapy with intraocular
      pressure ≥ 18 mm Hg and ≤ 40 mm Hg
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>1 year</time_frame>
    <description>Reduction in intraocular pressure relative to the pre-operative value will be assessed with the final measurement of success at twelve months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glaucoma medical therapy</measure>
    <time_frame>1 year</time_frame>
    <description>Level of glaucoma supplemental medical therapy with M12 and M24 as endpoint.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>MIDI Arrow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of MIDI Arrow</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MIDI Arrow</intervention_name>
    <description>Implantation of MIDI Arrow</description>
    <arm_group_label>MIDI Arrow</arm_group_label>
    <other_name>Glaucoma drainage device implantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patient, age 18 to 85 years, inclusive

          2. Patient has primary open angle glaucoma that is inadequately controlled on tolerated
             medical therapy with intraocular pressure greater than or equal to 18 mm Hg and less
             than or equal to 40 mm Hg

          3. Patient must have signed and dated the Informed Consent form

        Exclusion Criteria:

          1. Unwilling or unable to give informed consent or unable to return for scheduled
             protocol visits.

          2. Pregnant or nursing women.

          3. No light perception.

          4. Active iris neovascularization or active proliferative retinopathy.

          5. Iridocorneal endothelial syndrome.

          6. Epithelial or fibrous downgrowth.

          7. Pseudoexfoliative glaucoma

          8. Aphakia.

          9. Vitreous in anterior chamber for which a vitrectomy is anticipated.

         10. Corneal disease

         11. Acute, chronic or recurrent uveitis.

         12. Severe posterior blepharitis.

         13. Unwilling to discontinue contact lens use after surgery.

         14. Previous ophthalmic surgery, excluding phacoemulsification (cataract) surgery or
             corneal refractive surgery.

         15. Prior cataract surgery involving a conjunctival incision

         16. Need for glaucoma surgery combined with other ocular procedures except for cataract
             surgery or anticipated need for additional ocular surgery during the investigational
             period.

         17. Less than 0.1 (20/200) visual acuity in the non-test eye.

         18. Infectious conjunctivitis, a narrow-angle glaucoma, endophthalmitis, orbital
             cellulitis one, infection, severe dry eye, severe myopia, conjunctivitis fine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle M Riss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Mutualiste de Pessac, Pessac, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Mutualiste - Pavillon Ophtalmogique</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2012</study_first_submitted>
  <study_first_submitted_qc>March 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2012</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

